GV1001 not checked
Samsung Pharmaceutical Co., Ltd. · GemVax & Kael · Tertomotide 1.68mg · Tertomotide 0.84mg
FollowEvery change as it happens, and a Monday email
Trials
1 active
8 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Moderate to Severe Alzheimer's Disease
- Main trialPhase 3
- “The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).”In the company’s words, NCT05303701 on ClinicalTrials.gov
- Other names
- Tertomotide 1.68mg · Tertomotide 0.84mg · Tertomotide
Other drugs for Moderate to Severe Alzheimer's Disease
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up1
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jan 2028 | GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) | |
| Phase 3Completed | 17 Mar 2022 | Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) | |
| Phase 2Completed | Oct 2016 | A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH | |
| Phase 2Withdrawn | 31 Aug 2021 | GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) | |
| Phase 2Completed | 11 Oct 2024 | GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) | |
| Phase 2Completed | 3 Apr 2025 | GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) | |
| Phase 2Completed | 1 Sep 2025 | Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 | |
| Phase 1Completed | 25 Aug 2025 | Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026